- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BG00011, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- IPF
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Standard pulmonary rehabilitation program
- Other
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- GSK3915393, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Newport Beach, California • Jacksonville, Florida • St. Petersburg, Florida + 7 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- QAX576
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 3 more
- Conditions
- Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Iloprost Inhalation Solution (Ventavis)
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- 20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray
- Drug · Other
- Lead sponsor
- Cellular Sciences, inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Hialeah Gardens, Florida
- Conditions
- Pulmonary Fibrosis
- Interventions
- Placebo, CNTO 888 1 mg/kg, CNTO 888 5 mg/kg, CNTO 888 15 mg/kg
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 14 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- GLPG1690, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 781 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- ACT-064992 (macitentan), Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- Interstitial Lung Disease, Pulmonary Fibrosis
- Interventions
- [68Ga]CBP8, Gadoterate Meglumine
- Drug
- Lead sponsor
- Peter Caravan
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Deupirfenidone, Pirfenidone (PFD)
- Drug
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Palm Spring, California • Redding, California • North Dartmouth, Massachusetts + 7 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Simtuzumab, Simtuzumab placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
- Conditions
- Healthy Participants
- Interventions
- BMS-986278, Sildenafil, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Cypress, California • Miami, Florida
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Fibrosis Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- pirfenidone
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 40 Years to 84 Years
- Enrollment
- 1,058 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- South San Francisco, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- NIP292 tablet, NIP292 tablets
- Drug
- Lead sponsor
- The National Institutes of Pharmaceutical R&D Co. Ltd, China
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
- Other · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more
- Conditions
- Lung Diseases, Herpesvirus Infections
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Placebo, Pirfenidone, Deupirfenidone
- Drug
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 19 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BI 1819479, Placebo matching BI 1819479
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 12 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California